Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer

British Journal of Cancer

Volumn 86, Issue 5, 2002, Pages 819-827

  Magne N ^a   Fischel, J L ^a   Dubreuil, A ^a   Formento, P ^a   Marcie S ^a   Lagrange, J L ^a   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Cisplatin; Combination therapy; Fluorouracil; Head and neck cancer cell lines; Radiation; ZD1839

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GEFITINIB; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IRRADIATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; GENES, P53; HEAD AND NECK NEOPLASMS; HUMANS; QUINAZOLINES; RECEPTORS, GROWTH FACTOR; RECEPTORS, MITOGEN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 0037017877     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600103     Document Type: Article

References (50)

1. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas
2. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells
3. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
4. Concomitant B.I.D. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: Clinical and pharmacological data of a French multicenter phase II study
5. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivity
6. Ionizing radiation-induced MEK and ERK activation does not enhance survival of irradiated human squamous carcinoma cells
7. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers
8. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer
9. P53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series
10. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma
11. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing
12. Quantitative analysis of dose-effects relationships: The combined effects of multiple drugs or enzyme inhibitors
13. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa™), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
14. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer
15. Radiation-induced release of transforming growth factor α activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death
16. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil
17. Phase I trial of chimerized anti-epidermal growth factor receptor (anti-EGFR) antibody in combination with either once-daily or twice-daily irradiation for locally advanced head and neck malignancies
18. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003
19. Quantitative immunohistochemical analysis growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
20. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
21. Single-step DGGE-based mutation scanning of the p53 gene: Application to genetic diagnosis of colorectal cancer
22. Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors
23. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
24. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis
25. Enhancement of sensitivity of human squamous carcinoma cells to radiation by epidermal growth factor
26. Differences in EGF-related radiosensitization of human squamous carcinoma cells with high and low numbers of EGF receptors
27. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry
28. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma
29. Phase I study of chimerized anti-epidermal growth factor receptor (EGFR) monoclonal antibody, C225, in combination with cisplatin (CDDP) in patients (PTS) with recurrent head and neck and squamous cell carcinoma (SCC)
30. In vivo enhancement of tumor radioresponse by C225 anti-epidermal growth factor receptor antibody
31. Correlation of epidermal growth factor receptor and radiosensitivity in human maxillery carcinoma cell lines
32. Epidermal growth factor receptor expression and suramin cytotoxicity in vitro
33. Phase II study receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
34. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
35. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
36. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data
37. Epidermal growth factor-related peptides and their receptors in human malignancies
38. Characterization, quantification and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas
39. Radiation treatment decreases transforming growth factor alpha expression in squamous carcinoma of the tongue
40. Cell signaling by receptor tyrosine kinases
41. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
42. Concomitant cisplatin/5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results
43. Cell cycle regulation after exposure to ionizing radiation
44. Ionizing radiation stimulates existing signal transduction pathways involving the activation of epidermal growth factor receptor and erbB-3, and changes of intracellular calcium in A431 human squamous carcinoma cells
45. Head and neck cancer
46. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer
47. EGF receptor crosstalks with cytokine receptors leading to the activation of c-Jun kinase in response to UV irradiation in human keratinocytes
48. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy
49. Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer
50. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro